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A. Characterization of the motion stimulus.
A motorized motion testing device modelled after a
Ferris wheel was constructed. The cats rode alone in two
clear plastic boxes suspended from the ends of a 0.89 m beam
that rotated about a horizontal axle. The boxes were
counterrotated to keep the floor level. A parametric study
determined that the most provocative motion was a frequency
of 0.28 Hz (17 rpm), a value similar to that of other
species. A standard test was then defined as 30 min of
motion at 0.28 Hz followed by one min of observation at
rest. Susceptibility was determined in female cats by
testing them at two week intervals for five tests. Only
those responding on at least two tests were considered
adequately susceptible for inclusion in motion studies.
Roughly half of the population tested responded on none of
the screening tests, while roughly 10% responded at each
level of susceptibility, i.e. 10% responded on five of five
tests, 10% on four of five, etc (I).
A separate study determined that tests performed at two
week intervals resulted in no habituation to the motion
stimulus. Five weekly tests resulted in significant
habituation and five daily tests resulted in even more rapid
habituation. In both cases of habituation, the
2
susceptibility of the group recovered when tested two weeks
later. Further analysis revealed that the rate of
habituation was not related to the susceptibility of the
subjects (15). In all other motion studies, tests were
separated by at least two weeks unless otherwise stated.
The latency to the first retch was verified to fit the
Weibull distribution, as it does for human subjects. A
program was written to analyze the latency data, fitting it
to the two parameter Weibull distribution. Of particular
importance was that the program was designed to handle right
censored data (when at least one subject does not respond),
a situation which applies to virtually every test (6).
B. Xylazine-induced emesis.
A dose-response curve was determined for xylazine
administered subcutaneously. The results led to the use of
the dose of 0.66 mg/kg as a standard emetic drug challenge
in subsequent studies. The emetic effect of xylazine was
prevented by the alpha-2 noradrenoceptor antagonist,
yohimbine, which did not prevent motion sickness. The
asymmetry of the drug response of the two stimuli was also
observed for scopolamine, which prevented motion sickness
but not xylazine-induced emesis. This result verified that
provocative motion and xylazine use different predominant
pathways to trigger emesis, as had been suggested based on
the observation that xylazine but not motion requires an
intact area postrema for the induction of emesis. The study
also observed a correlation between the threshold dose for
xylazine-induced emesis and the susceptibility to
provocative motion, leading to the suggestion that
susceptibility to emetic stimuli in general is a fundamental
characteristic of the individual that may occur at the level
of the emetic pattern generator (2),
Cannulae were implanted in the rostral portion of the
fourth ventricle under appropriate anesthesia and sterile
conditions. Samples of CSF were collected at twenty min and
again just before motion testing. A third sample was
collected immediately after vomiting or after 30 min of
motion, whichever occurred first. The fourth and fifth
samples were collected at twenty min intervals thereafter.
On the day after the motion test, control samples of CSF
were collected at the same time intervals and the same time
of day.
Analysis by HPLC with coulometric detection (conducted
by ESA, Inc) identified 37 compounds in an adequate number
of samples for statistical analysis. Most compounds were
derivatives of tyrosine or tryptophan. None of the
compounds varied as a function of motion testing, either
with or without vomiting. However, those cats that did
vomit had lower baseline levels of dopamine and its
metabolites, DOPACand HVA, the serotonin metabolite 5-HIAA,
the norepinephrine metabolite MHPGS04and uric acid. Thus,
these transmitter systems are likely candidates for a role
in the motion sickness process (9). In addition, comparison
of the levels of the constituents on the test day with those
on the control day which followed, when habituation would
have been evident had they been tested, revealed an increase
in the minor metabolites 3,4 dihydroxybenzoic acid and 3,4
dihydroxymandelic acid (7).
Another set of CSF samples were sent to NASA Ames for
analysis of vasopressin levels. Vasopressin in the CSF did
not change as a function of provocative motion with or
without vomiting. However, those cats that did vomit had
lower baseline levels of vasopressin than did nonresponding
ones (4).
A. Agonist effects on motion sickness.
In a logical follow-up experiment to the CSF analysis,
the 5-HTIA partial agonist buspirone was found to block
motion sickness (3). Subsequently, three additional
agonists also were found to be effective (10,11)(Fig I).
The rank order of potency is roughly the same as their order
of binding affinity at the 5-HTIA receptor. The prototype
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agonist, 8-OH-DPAT has also been reported to be effective in
preventing motion sickness in the Japanese house musk shrew
(Matsuki, personal communication). Of the agonists, only
buspirone produced nonspecific behavioral effects at doses
that suppressed motion sickness and it is the least
selective for the 5-HT_A receptor. Unfortunately, it is the
only one available for use in human subjects in this
country. The only attempt to evaluate the efficacy of
buspirone against motion sickness in human subjects used
only one dose, 5 mg, which is below the anxiolytic dose
range of 20-60 mg/day. The data from the cat make it clear
that only doses above the anxiolytic range are effective.
I00
0
+-
0
L)
so
ch
o--
_I]
u
4-
q)
r,-
0 !
2
DPAT
, f
!
lo Poo _,ooo _,oDo
[)o5e ,
Figure I. Effects of four 5-HTIA agonists on motion
sickness in the cat. Doses are in microgram of drug per kg
body weight on a log scale. Flesinoxan dose-response curves
were determined twice at different pretreatment times.
The identification of the 5-HTIa site as relevant was
verified by reversing the effect of 8-OH-DPAT with the
antagonist (-)propranolol (11). Subsequent work
demonstrated that the agonists can be differentiated on the
basis of the antagonists that are effective in reversing the
response. Specifically, the suppression of motion sickness
by flesinoxan can not be reversed by (-)propranolol (Table
I). Further, the effect of flesinoxan but not that of 8-OH-
DPAT was reduced by the antagonist/partial agonist NAN-190
(Figure I). This work is providing an important
contribution to the understanding of the 5-HTIA receptors
and their pharmacology.
Table 1. (-)Propranolol (1.0 mg/kg) did not reverse the
effect of flesinoxan. This dose of (-)propranolol
previously was determined to shift the DPAT dose-response
curve to higher doses (11). All doses in mg/kg.
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Figure 2. NAN-190 is dose-additive with 8-OH-DPAT but
antagonistic to flesinoxan. Solid dots, agonist alone.
Open dots, 3 mg/kg of NAN-190 plus treatment on the
abscissa. Lower doses of NAN-190 alone and in combination
with the agonists had no effect.
B. Relevance of pre- vs postsynaptic sites.
It is of theoretical and practical importance to
differentiate between presynaptic and postsynaptic sites of
action of the above agonists. Several lines of evidence
lead to the conclusion that the relevant sites are located
postsynaptically.
Two lines of evidence were obtained by a test of the
alternative hypothesis, that 5-HTIA agonists suppressed
motion sickness by stimulating presynaptic receptors,
leading to a decrease in 5-HT neuronal firing. Attempts
were made to mimic the antiemetic effect of the agonists by
depleting the 5-HT terminals of 5-HT with the synthesis
inhibitor, PCPA, and by blocking the postsynaptic receptors
with the nonspecific antagonist, metergoline. With each
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drug, there was no antiemetic effect; rather, there was a
tendency for increased motion sickness (11).
A third line of evidence was derived from the reversal
of the antiemetic effect of 8-OH-DPAT by (-)propranolol.
This antagonist has been reported to block postsynaptic
receptors but not presynaptic receptors following systemic
administration, as was done in the motion sickness
experiment (11).
Finally, the results from an experiment with the
benzodiazepine, lorazepam are relevant. Doses of lorazepam
that decreased motion sickness also produced ataxia. Even
higher doses had no effect on xylazine-induced emesis (10).
In contrast, 5-HTIA agonists begin to suppress xylazine-
induced emesis over the dose range that inhibits motion
sickness (3,10). Doses of benzodiazepines that produce
ataxia in the cat also completely suppress the firing of
5-HT neurons. Thus, if the 5-HTIA agonists were acting
presynaptically to suppress emesis, then lorazepam should
also have suppressed xylazine-induced emesis. From the
above four lines of reasoning, it is concluded that
postsynaptic sites of action are relevant to the antiemetic
effect of 5-HTIA agonists.
C. Anatomical location of antiemetic 5-HT_A receptors.
It is also of theoretical and practical importance to
determine the anatomical location of the relevant 5-HTIA
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receptors. As described below, the most likely site of
action is on or near the emetic pattern generator. The
broad spectrum of antiemetic effects defies the old
conventional wisdom that only those drugs that suppress
respiration have a general antiemetic effect. The relevant
5-HT1A sites are currently being further characterized so
that they may be used as one marker for the mapping of
neurons in the diffusely organized emetic pattern generator.
As described above, motion sickness and xylazine rely
on different predominant pathways to trigger the emetic
reflex. Both 8-OH-DPAT and buspirone inhibit not only
motion sickness but also xylazine-induced emesis (3,10).
These agonists suppress cisplatin-induced emesis (5,10),
which relies on the area postrema and vagal afferents.
8-OH-DPAT also suppresses emesis elicited by the 5-HT1D
agonist, RU 24969 (12) and by orally administered copper
sulfate, which relies on vagal afferents. In the latter
experiment, the uniformly emetic dose of 10 mg of copper
sulfate in 20 ml was administered via a nasogastric tube.
The dose of 0.64 mg/kg of 8-OH-DPAT abolished the emetic
response. Thus, these agonists exhibit a very wide spectrum
of antiemetic effects. The most parsimonious explanation is
that the receptors are located on or near the emetic pattern
generator.
While unlikely, it is possible that each predominant
pathway possesses inhibitory 5-HTIA receptors. If this is
the case, then they would act to suppress the vestibular
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signal and/or the formation of the mismatch signal. This
leads to the prediction that the agonists would interfere
with the development of habituation to motion sickness. In
a direct test of this interpretation, cats were exposed to
three daily tests with provocative motion both with and
without suppression of motion sickness by 8-OH-DPAT, and
then tested on the fourth day with only administration of
saline. The suppression of motion sickness by the agonist
did not result in a different incidence of motion sickness
than was observed following daily motion without drug. This
experiment demonstrated that the inhibitory 5-HTIA sites
were located somewhere past the central comparator (e.g. on
the emetic pattern generator) and that the emetic response
need not be expressed for habituation to provocative motion
to occur. These results also demonstrate that suppression
of motion sickness by this mechanism during exposure to a
provocative environment, such as microgravity, will not
interfere with the development of habituation to the emetic
stimulus (16).
To summarize, several 5-HTIA agonists suppress motion
sickness as well as emesis elicited by a wide range of
stimuli. The antiemetic effect may be reversed by 5-HT1A
antagonists in a complex manner that may lead to new
insights in 5-HT receptor pharmacology. The relevant 5-HT1A
receptors are located postsynaptically and are probably to
be found on neurons in the emetic pattern generator.
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The 5-HT3 antagonists have been reported to be highly
effective in preventing emesis elicited by radiation and by
cancer chemotherapeutic drugs. Representatives of this drug
class from different chemical families were tested in the
cat and found to not prevent either motion sickness or
xylazine-induced emesis, even at doses that completely
abolished cisplatin-induced emesis (8). This work is
consistent with a report that 5-HT3 antagonists are
ineffective in preventing motion sickness in human subjects.
The 5-HT agonist, RU 24969, was found to be an emetic
agent in the cat. This action was not mediated through
catecholaminergic, 5-HT2, 5-HT3, 5-HT1A or 5-HTlc receptors.
Because the cat does not have the 5-HT1B receptor, only the
5-HT1D site could have mediated this effect (12). This
anatomical location remains unidentified. However, other
work in this laboratory has determined that the 5-HT1D
agonist, sumatriptan, which does not cross the blood brain
barrier, is a powerful emetic in the cat in the dose range
of 0.03 to 0.1 mg/kg. Thus, RU 24969 also may exert its
emetic action by acting at some site outside of the blood
brain barrier. In the course of these investigations, it
was observed that the putative nonspecific 5-HT antagonist,
methysergide also elicited emesis (11). This drug has been
reported to act as an agonist on some 5-HT receptor subtypes
in some paradigms. While the relevant site for the emetic
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effect of methysergide had not been determined, it is clear
that this drug is not suitable for use as an antagonist in
the cat,
The 5-HTIc and 5-HT2 receptor antagonist, mesulergine,
did not alter motion sickness in the cat (11), making a role
for these receptors unlikely. It has been reported that
much higher doses of a 5-HT2 and alpha adrenoceptor
antagonist prevented motion sickness in the Japanese house
musk shrew. It is not clear if this discrepancy results
from the dose ranges tested, species differences or the
presence of an alpha adrenoceptor blockade component.
However, 3 mg/kg of the alpha adrenoceptor antagonist,
phentolamine, does not alter motion sickness in the cat
despite a prominent nictitating membrane response to the
drug (unpub. obs.).
A. Antimuscarinic mechanisms.
The standard motion sickness preventative, scopolamine,
was found to inhibit motion sickness (18;Fig 3). In an
effort to identify which of the three muscarinic receptor
subtypes were involved, the M1 and M2 selective antagonist
idaverine was tested. Idaverine completely failed to
prevent motion sickness over a dose range that had an upper
limit due to the appearance of emetic effects. Comparison
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of the affinities of scopolamine and idaverine for
muscarinic receptor subtypes and the molar doses of each
drug used led to the suggestion that blockade of the M3
subtype is the critical component of the action of
scopolamine (17). If subsequent testing confirms this
hypothesis, then it will become possible to prevent motion
sickness with an M3 subtype selective antagonist, a drug
which will clearly have far fewer side effects that does
scopolamine, in o
Figure 3 Dose-response t
• {
curve for the suppression o , • __
of motion sickness by
scopolamine.
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In addition, a test with the peripherally acting
nonspecific muscarinic antagonist, methscopolamine, was
performed. While the drug had no effect on the incidence of
emesis, it did alter the symptom rating scale. This
demonstrates that rating scales use measures that can be
blocked by a drug which has no effect on motion-induced
vomiting. Thus, the use of rating scales in lieu of an
emetic response is highly questionable (18).
B. Antihistaminergic mechanisms.
The common antihistamine, diphenhydramine, did not
prevent motion sickness over the dose range tested, despite
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the administration of the drug 12 and then again I hour
before motion testing. However, the histamine synthesis
inhibitor, alpha-fluoromethylhistidine, did significantly
decrease motion sickness (19). Thus, the histamine
transmitter system is involved in feline motion sickness as
it is in other species. Further, these results suggest that
this synthesis inhibitor may provide greater suppression of
motion sickness than standard antihistamines.
C. Amphetamine
Twenty cats received the doses of 0.008, 0.031, 0.125
and 0.5 mg/kg, ten of which _eceived the additional doses of
0.0625, 0.25 and 1.0 mg/kg. None of the doses tested
significantly decreased the incidence of motion sickness or
significantly increased the latency to the first retch.
This is in contrast to recent reports of the effectiveness
of sympathomimetics in the alleviation of motion-induced
nausea. One possible explanation is that there are species
differences. Another possibility is a difference in the
measure used. The data from the cat used emetic events as
the measure, while recent work with human subjects uses
nausea as an end point. The possible confounding by
motivational variables in studies with sympathomimetics was
suggested in the literature over two decades ago. Early
work with sympathomimetic drugs in human subjects which used
vomiting as the measure obtained negative results. The
reduction of nausea measured by more recent tests would be a
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valuable clinical response. However, it is of importance to
the NASA mission to determine if sympathomimetics suppress
vomiting as well as nausea in human subjects (18).
D. Adenosinergic drugs.
The analysis of the constituents of CSF revealed that
levels of uric acid differed in susceptible and
nonsusceptible cats. The role and origin of uric acid in
the CNS are unknown, but it may be an inactive metabolite of
adenosinergic transmission. Accordingly, the role of
adenosine receptor subtypes in emetic mechanisms was
investigated. The AI agonist CHA was found to elicit emesis
with a steep dose-response curve, i.e. only one of ten cats
vomited at the dose of 0.006 mg/kg, while nine of ten
vomited at the dose of 0.01 mg/kg. All ten vomited at the
dose of 0.03 mg/kg, with an average of 6 emetic events. The
AI antagonist CPT abolished the emetic response to 0.01
mg/kg. Emesis elicited by 0.01 mg/kg of CHA was not
appreciably reduced by 0.1 or 0.3 mg/kg of the nonspecific
adenosine antagonist CGS 15943 and was only marginally
reduced by 0.1 mg/kg of the nonspecific antagonist PD
115199.
The somewhat A2 selective agonist CV 1808 began to
elicit emesis at the dose of 0.03 mg/kg and elicited
vomiting in eight of ten cats by the dose of 0.3 mg/kg. The
emesis was not reduced by 0.3 mg/kg of CPT, 0.1 mg/kg and
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0.3 mg/kg of CGS 15943 or 0.03 and 0.1 mg/kg of the somewhat
A2 selective antagonist DPMX. Thus, it is not clear that CV
1808 elicited emesis via adenosinergic mechanisms.
The doses of 0.1 mg/kg of CGS 15943, 0.1 mg/kg of CPT
and 0.1 mg/kg of PD 115199 had no effect on motion sickness.
There was only a marginal increase in the latency to the
first retch following 0.3 mg/kg of CGS 15943 and 0.3 mg/kg
of CPT.
In summary, stimulation of A1 receptors elicits emesis
that can be reversed by selective but not by nonselective
antagonists. The Az agonist tested elicited emesis but the
response was not reversed by adenosine antagonists. There
was only a marginal reduction in motion sickness following
administration of A1 antagonists, making this mechanism
unsuitable for the reduction of motion sickness.
E. Opioid antagonist.
The nonselective opioid antagonist naloxone was tested
in ten cats using a 10 min pretreatment time rather than the
one hour used in previous tests in the cat. The doses of
0.001 and 0.01 mg/kg had no effect and the dose of 0.1 mg/kg
produced a marginal decrease in the latency to the first
retch. A previous study by one of the authors (GHC) using
different doses and pretreatments obtained larger increases.
Thus, nonselective opioid antagonism results in an increase
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in motion sickness in cats as it appears to do in human
subjects.
F. Peptides.
Continuous infusion of thyroid releasing hormone (TRH)
has been reported to enhance the rate of recovery from
unilateral labyrinthectomy. To investigate a possible role
of TRH in the suppression of motion sickness, stable
analogues of TRH must be used because authentic TRH has a
half life of only a few minutes following systemic
administration. The stable analogue MK 771, in which both
end moities of the tripeptide are substituted, elicited
emesis in half the cats at the dose of 0.003 mg/kg and
virtually all the cats at 0.01 and 0.1 mg/kg. The
monosubstituted stable analogue CG 3703 elicited emesis in
three at 0.001 mg/kg, in four at 0.0018 mg/kg and in seven
at 0.003 mg/kg. The monosubstituted analogue at the other
end moiety was not available for testing to evaluate the
role of the end moieties in the emetic response. It is
concluded that the stable analogues tested are extremely
powerful emetic agents, as TRH itself was subsequently found
to be in dogs.
The role of cholecystokinen (CCK) was also investigated
using the CCKA antagonist L 364,718 and the CCKB antagonist
L 364-260. Each compound was tested at the doses of 0.03,
0.1 and 0.3 mg/kg. Neither drug altered either the
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incidence or the latency to motion sickness. Both subtypes
o5 CCK receptor were blocked by combining the dose o5 0.1
mg/kg of each agent before motion testing. Again, there was
no significant effect on motion sickness. This combination
was similarly ineffective in preventing xylazine-induced
emesis. Thus, CCK does not appear to have a role in motion
sickness, though other researchers have clearly implicated
it in the suppression of feeding.
G. Cannabinoid
The cannabinoid derivative, N-methyllevantradol, was
evaluated for a possible general antiemetic effects, as it
has been reported to suppress emesis elicited by cancer
chemotherapy in human subjects and in cats. The doses of
0.001, 0.003 and 0.01 mg/kg produced no effect on xylazine-
induced emesis, despite the testing of doses that produce
measurable inhibition of cisplatin-induced emesis in the
cat. The negative results led to the decision to not
attempt to prevent motion sickness with the cannabinoid.
H. Cognitive enhancers (nootropics).
Cognitive enhancers (nootropics) improve learning rate,
decrease learning deficits elicited by scopolamine or
cerebral hypoxia, exert a neuroprotective effect under
conditions of metal application or severe hypoxia and exert
19
anticonvulsant effects. Researchers from the Soviet Union
and Eastern block nations report that these drugs reduce
motion sickness in human subjects, as do anticonvulsant
drugs.
Accordingly, preliminary test were conducted in cats.
The doses of 100 and 300 mg/kg of piracetam and 3 and 10
mg/kg of aniracetam had no significant effect on emesis
elicited by 0.66 mg/kg of xylazine in cats. In two highly
susceptible cats, the dose of 100 mg/kg of piracetam
abolished motion sickness. This drug class warrants further
investigation as a therapeutic strategy for motion sickness,
despite its absence of general antiemetic effects.
I. Dextromethorphan/sigma ligands.
Recently, the dextromethorphan binding site has been
characterized as synonymous with the nonpsychotomimetic
sigma site. The issue is currently controversial, with
possible modulatory roles on glutaminergic transmission
described. The antitussives that bind to the
dextromethorphan/sigma site also have anticonvulsant
effects.
The safe, over-the-counter drugs dextromethorphan and
caramiphan, at the doses of I and 10 mg/kg, had no effect on
xylazine-induced emesis. The doses of 0.3, I and 3 mg/kg of
dextromethorphan were further tested in the motion sickness
paradigm. The doses of I and 3 mg/kg marginally reduced the
2O
incidence of emesis and significantly increased the latency
to the first emetic event. The dose of 3 mg/kg also
produced mild ataxia in the cats. However, the more potent
ligand, DTG, had no effect on motion sickness over the dose
range of 0.03 to 3.0 mg/kg. On interpretation of this
discrepancy arises from a model in which there are four
subtypes of sigma receptor. While both dextromethorphan and
DTG bind to the sigma-1 receptor, only dextromethorphan
bound to the sigma-2 subtype. Thus it is possible ataxia-
inducing doses of sigma-2 ligands may moderately suppress
motion sickness.
I. Review articles.
Dr. Crampton initiated and edited the book, M_%J.9._......_n.#
_P_c_...S.j.c.kD_#._, CRC Press, 1990. Both GHC and JBL
contributed chapters (13,14). A preliminary review of the
5-HTIA agonist work also appeared in the proceedings of a
symposium (20).
K. Role of the cerebellum in motion sickness
Nine motion susceptible cats received lesions of the
nodulus and uvula and were tested on the Ferris wheel
apparatus for up to nine post operative tests spaced at
least two weeks apart. Two of the cats became refractory to
motion sickness, and two others displayed a reduced
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susceptibility. Preliminary examination of the sectioned
and stained brains indicates that only the largest lesions
were effective. Further study of the brains is required
before a manuscript is prepared.
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